Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria
Dermatology · 18.04.2026 · 242 (4) · 471-481
DOI: 10.1159/000551762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology, online erschienen am 18.04.2026. Verfasst von Anqi Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Omalizumab is an effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU), although treatment responses vary significantly. While fast and slow responders are well characterized, the profile of super responders (SRs) remains poorly understood. This study aimed to identify clinical and laboratory predictors of super response (SR) and poor/non-response (PR) to omalizumab in refractory CSU.
Methods
This retrospective study analyzed 307 CSU patients treated with omalizumab at a UCARE center between January 2023 and December 2024. SR was defined as achieving Urticaria Activity Score (UAS) = 0 within 1 week and sustained control (UAS7 ≤6, Urticaria Control Test [UCT] >12); PR was defined as UCT
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
- Chongqing Municipal Health Commission Key Laboratory of of Immunological Skin Diseases, Chongqing, China.
- Institute of toxicology, school of preventive medicine, Army Medical University, Chongqing, China.
- Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China, drsongzq@tmmu.edu.cn.
- Chongqing Municipal Health Commission Key Laboratory of of Immunological Skin Diseases, Chongqing, China, drsongzq@tmmu.edu.cn.
- Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China, chenqq0548@tmmu.edu.cn.
Zitieren
APA
Chen, A., Yang, H., Yang, X., Huang, X., Li, S., Deng, S., Wang, H., Song, Z., & Chen, Q. (2026). Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria. Dermatology, 242(4), 471-481. https://doi.org/10.1159/000551762
Vancouver
Chen A, Yang H, Yang X, Huang X, Li S, Deng S, et al. Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria. Dermatology. 2026;242(4):471-481. doi:10.1159/000551762
BibTeX
@article{Chen2026,
author = {Chen, Anqi and Yang, Huan and Yang, Xianjie and Huang, Xuewei and Li, Shifei and Deng, Sisi and Wang, Huan and Song, Zhiqiang and Chen, Qiquan},
title = {Predictors of Super/Poor Omalizumab Response in Chinese Refractory Chronic Spontaneous Urticaria},
journal = {Dermatology},
year = {2026},
volume = {242},
number = {4},
pages = {471--481},
doi = {10.1159/000551762}
}
EUVIMED